Cargando…
Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
BACKGROUND: Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing C...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792612/ https://www.ncbi.nlm.nih.gov/pubmed/26985370 http://dx.doi.org/10.1093/ckj/sfv133 |
_version_ | 1782421275390509056 |
---|---|
author | Godaly, Gabriela Carlsson, Ola Broman, Marcus |
author_facet | Godaly, Gabriela Carlsson, Ola Broman, Marcus |
author_sort | Godaly, Gabriela |
collection | PubMed |
description | BACKGROUND: Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing CRRT fluid on phosphate homeostasis. METHODS: We retrospectively analysed 112 patients treated with CRRT at Skåne University Hospital, Sweden. The control group was treated with Hemosol(®) B0 (no phosphate; n = 36) as dialysis and replacement fluid, while the study group received Phoxilium(®) (phosphate; n = 76) as dialysis fluid and Hemosol(®) B0 as replacement fluid. RESULTS: Hypophosphataemia (<0.7 mM) occurred in 15% of the treatment days in the control group compared with 7% in the study group (P = 0.027). Magnesium substitution was reduced by 40% in the study group (P < 0.001). No differences in acid–base parameters were detected between the groups. CONCLUSIONS: In this larger cohort, we could confirm that Phoxilium(®) reduced the episodes of hypophosphataemia during CRRT. A beneficial effect on magnesium balance could also be observed. |
format | Online Article Text |
id | pubmed-4792612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47926122016-03-16 Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy Godaly, Gabriela Carlsson, Ola Broman, Marcus Clin Kidney J Acute Kidney Injury BACKGROUND: Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing CRRT fluid on phosphate homeostasis. METHODS: We retrospectively analysed 112 patients treated with CRRT at Skåne University Hospital, Sweden. The control group was treated with Hemosol(®) B0 (no phosphate; n = 36) as dialysis and replacement fluid, while the study group received Phoxilium(®) (phosphate; n = 76) as dialysis fluid and Hemosol(®) B0 as replacement fluid. RESULTS: Hypophosphataemia (<0.7 mM) occurred in 15% of the treatment days in the control group compared with 7% in the study group (P = 0.027). Magnesium substitution was reduced by 40% in the study group (P < 0.001). No differences in acid–base parameters were detected between the groups. CONCLUSIONS: In this larger cohort, we could confirm that Phoxilium(®) reduced the episodes of hypophosphataemia during CRRT. A beneficial effect on magnesium balance could also be observed. Oxford University Press 2016-04 2015-12-19 /pmc/articles/PMC4792612/ /pubmed/26985370 http://dx.doi.org/10.1093/ckj/sfv133 Text en © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Acute Kidney Injury Godaly, Gabriela Carlsson, Ola Broman, Marcus Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy |
title | Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy |
title_full | Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy |
title_fullStr | Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy |
title_full_unstemmed | Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy |
title_short | Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy |
title_sort | phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy |
topic | Acute Kidney Injury |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792612/ https://www.ncbi.nlm.nih.gov/pubmed/26985370 http://dx.doi.org/10.1093/ckj/sfv133 |
work_keys_str_mv | AT godalygabriela phoxiliumreduceshypophosphataemiaandmagnesiumsupplementationduringcontinuousrenalreplacementtherapy AT carlssonola phoxiliumreduceshypophosphataemiaandmagnesiumsupplementationduringcontinuousrenalreplacementtherapy AT bromanmarcus phoxiliumreduceshypophosphataemiaandmagnesiumsupplementationduringcontinuousrenalreplacementtherapy |